Kåre Schultz på vej væk fra Teva Pharmaceutical | www.euroinvestor.dk Nyheder - www.euroinvestor.dk
Business-overblik: Kåre Schultz har planlagt sit farvel til topjob i Teva
Kåre Schultz forlænger kontrakt med Teva — MedWatch
Kåre Schultz er tavs om mulig kontraktforlængelse: “Det skaber bare unødvendige rygter”
Teva's Copaxone Successors Are Still Far From Success | Ctech
Ex-pharmaceutical company boss faces insider trading charges over Teva deal | The Times of Israel
Now That Teva Has Stabilized, Teva Stock Looks Undervalued | InvestorPlace
Teva taps new CFO, hikes legal set-aside to more than $1B as opioid deal falters | Fierce Pharma
Nedtælling for Kåre Schultz: “Inden for de næste 12 måneder vil de finde min afløser”
Kåre Schultz får ikke opfyldt ønske om bestyrelsespost hos Teva — MedWatch
Cureatr to Be Named Top Place to Work for Work Flexibility and Vacation and Time off in Muse Vibe Awards 2022
Teva Announces Exclusive First-to-File Launch of a Generic Version of Cialis® in the United States | Business Wire
Teva takes 2nd long-acting schizophrenia drug into phase 3
Teva: Er det nu Kåre? | Nordnet
Teva to expand into long-acting Schizophrenia injectable medication - LifeSci Voice
Teva takes 2nd long-acting schizophrenia drug into phase 3
Kåre Schultz får lønforhøjelse på 26 mio. kr. — MedWatch
Teva USA
Teva CEO Kåre Schultz discusses company's latest quarter and opioid settlement - YouTube
Kåre Schultz forlænger med Teva: Får op til 26 mio. kr. mere i løn
Teva CEO Kåre Schultz discusses company's latest quarter and opioid settlement - YouTube
Teva to expand into long-acting Schizophrenia injectable medication - LifeSci Voice
Teva: Er der endelig lys forude? - ProInvestor
Teva CORE | Comprehensive Oncology Reimbursement Expertise
